The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting
Open Access
- 25 April 2019
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-11
Abstract
Little is known about the pathway to diagnosis of lymphoma in Sub-Saharan Africa, despite the increased risk of lymphoma in people living with HIV (PLHIV). The challenges of diagnosis in this setting include diagnostic confusion with extrapulmonary tuberculosis (EPTB), which commonly causes lymphadenopathy in PLHIV. We analysed the time to diagnosis and treatment in patients using predetermined time intervals. Univariate and multivariable analyses were performed to determine the relationship between patient and disease-specific variables with delays to diagnosis. We were particularly interested in the impact of HIV, empiric tuberculosis therapy and fine-needle aspirate for cytology (FNAC) in contributing to delay. Patients (n = 163), 29% HIV-infected, waited a median of 4 weeks before seeking medical attention. It took a median of 7 weeks for the diagnosis of lymphoma to be made from the time the patient sought medical attention, termed the healthcare practitioner interval. In multivariable logistic regression analysis, diagnostic delay > 6 weeks was associated with late-stage disease (OR 2.3, 95% CI 1.1–5.2) and Hodgkin lymphoma (HL) (OR 3.0, 95% CI 1.1–8.0). HIV status was not associated with diagnostic delay (OR 0.9, 95% CI 0.3–2.2). The median time to diagnosis was a median of 4 weeks longer for patients on tuberculous (TB) therapy (n = 16, p = 0.28) and patients who underwent an FNAC (n = 63, p = 0.04). Where FNAC was performed, it was diagnostic for lymphoma in only 11%. Diagnostic delay was not associated with overall survival. Time-to-diagnosis of lymphoma in South Africa was similar to that reported from high-income countries and shows significant periods of delay between the onset of symptoms to diagnosis and treatment. The longest period of delay was in the health practitioner interval. Education regarding the significance of lymphadenopathy for both patients and health care practitioners and appropriate investigative steps preferably by best-practice algorithms specific to TB-endemic areas are needed to shorten the time-to-diagnosis of lymphoma.Keywords
Funding Information
- Foundation for the National Institutes of Health (D43TW010543)
This publication has 21 references indexed in Scilit:
- Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research NetworkBMC Hematology, 2013
- Non-Hodgkin lymphoma: the clinician's perspective—a view from the receiving endLaboratory Investigation, 2013
- The Andersen Model of Total Patient Delay: A Systematic Review of Its Application in Cancer DiagnosisJournal of Health Services Research & Policy, 2012
- Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapyAIDS, 2011
- Human Immunodeficiency Virus Infection and Hodgkin's Lymphoma in South Africa: An Emerging ProblemAdvances in Hematology, 2011
- Cancer as a Cause of Death among People with AIDS in the United StatesClinical Infectious Diseases, 2010
- Lymphoma: variations in time to diagnosis and treatmentEuropean Journal of Cancer Care, 2006
- Utility of Fine-Needle Aspiration As a Diagnostic Technique in LymphomaJournal of Clinical Oncology, 2004
- An audit of delays in diagnosis and treatment of lymphoma in district hospitals in the northern region of the United KingdomClinical and Laboratory Haematology, 2000
- The value of wide-needle aspiration in the diagnosis of tuberculous lymphadenitis in AfricaAIDS, 1993